Tirzepatide in Houston, with the real clinical process that makes results stick.
A once-weekly GLP-1/GIP medication for chronic weight management, prescribed only after lab work and a provider consultation. Individual results vary.
A once-weekly injection for chronic weight management.
Tirzepatide is a dual-incretin agonist — it activates both GLP-1 and GIP receptors, the two hormone pathways your body uses to regulate appetite, blood sugar, and nutrient processing. In a head-to-head trial of the brand-name products, tirzepatide produced greater average weight loss than semaglutide; individual results vary.
Brand-name tirzepatide products are FDA-approved: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. When your provider determines it is clinically appropriate and it is permitted under current FDA rules, they may instead prescribe a compounded tirzepatide preparation from a licensed pharmacy.
Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality, and compounded tirzepatide is not a generic version of Mounjaro or Zepbound. We discuss the regulatory and quality differences during consultation so you understand exactly what you’re being prescribed and why.
Tirzepatide is one tool, and long-term results depend on treating it as part of a real metabolic conversation that includes sleep, stress, physical activity, and protein. The medication makes the work easier; it doesn’t replace the work.
The case for tirzepatide, honestly.
We choose between tirzepatide and semaglutide based on your history and goals. Here’s how we think about it.
Dual incretin action
Activates both GLP-1 and GIP receptors. How much the GIP component contributes is still being studied; in a head-to-head trial, tirzepatide produced greater average weight loss than semaglutide.
Evidence: Strong · SURMOUNT-1 + SURPASS trialsLarger weight loss in trials
SURMOUNT-1 showed mean reductions of ~16%, ~21.4%, and ~22.5% at 5mg, 10mg, and 15mg doses over 72 weeks. For comparison, semaglutide STEP-1 trials averaged ~14.9%. Real-world response varies; trial averages aren’t promises.
Evidence: Strong · Direct head-to-head data emergingSide-effect profile is workable
GI side effects (nausea, constipation, fullness) are real but generally manageable with slow dose titration. GI effects often lessen over time at a stable dose. We adjust dose timing and titration speed individually.
Evidence: Consistent across clinical trialsTirzepatide vs Semaglutide.
The two leading GLP-1-class medications in 2026. They share mechanisms, but the differences are clinically meaningful — and the right choice depends on your specific situation.
Semaglutide
Single-receptor agonist (GLP-1). Longest track record. FDA-approved as the brand-name products Ozempic (2017, type 2 diabetes) and Wegovy (2021, weight management).
- FDA-approved cardiovascular risk-reduction indication (Wegovy)
- Chosen based on your history and goals
- GI side effects common during titration
- Manufacturer savings programs often more accessible
Tirzepatide
Dual-receptor agonist (GIP + GLP-1). FDA-approved as the brand-name products Mounjaro (2022, type 2 diabetes) and Zepbound (2023, weight management; 2024, obstructive sleep apnea in obesity).
- Greater average weight loss than semaglutide in a head-to-head trial
- May be considered for patients who plateau on semaglutide
- Some patients tolerate it better; others find it harder
- Newer indications expanding (sleep apnea in obesity, others under review)
Tirzepatide is a tool. Foundations are the work.
Clinical trial data is impressive. Real-world long-term outcomes depend heavily on what you build alongside the medication — sleep, physical activity, nutrition, and stress management. We treat that work as part of the program, not as fine print.
The medication makes the work possible. It doesn’t replace it.
Tirzepatide reduces appetite for many patients. That creates an opening. What fills that opening determines whether the results last beyond the prescription.
- Adequate protein intake, which may help limit lean mass loss during weight loss
- Daily movement — walking counts, and consistency beats intensity
- Sleep, stress, and alcohol — the three biggest hidden derailers
- An exit plan from day one, whether you taper or stay on therapy long-term — discussed openly during our metabolic reset program
From consultation to first injection, in real medicine.
Tirzepatide prescribing follows the same clinical pattern as any other thoughtful prescribing decision — proper workup first, then a decision based on what your labs and history actually show.
Initial consultation
In person at our Houston clinic. We discuss your full medical history, what you’ve tried, current weight and metabolic picture, and whether tirzepatide is the right fit. No prescription written this day.
Comprehensive lab work
A full metabolic workup at our clinic or Quest near you. Pancreatic and thyroid contraindication screening included.
Protocol design
Your provider designs your specific protocol — starting at 2.5mg weekly with a measured titration schedule, route (subcutaneous, weekly), and monitoring cadence. We discuss expected timeline, side effects, and how we’ll respond if titration needs to slow.
First injection
Your prescription — an FDA-approved brand-name product or, where clinically appropriate, a compounded preparation (compounded medications are not FDA-approved) — with detailed dosing instructions. We provide injection training (subcutaneous), side-effect guidance, and clear expectations: appetite changes often begin early, weight loss builds gradually, and individual results vary.
Monitor & adjust
Structured check-ins at 4, 12, and 24 weeks. Lab repeat at 12 and 24 weeks. We adjust dose based on actual response and tolerability — not on a fixed escalation schedule. After the initial treatment phase, we discuss the transition into ongoing metabolic care.
Ready to start the conversation?
A 45-minute consultation with one of our providers. We’ll review your specific situation and decide together whether tirzepatide fits — or whether something else makes more sense for what you’re working on.
What tirzepatide can — and can’t — do.
The evidence for tirzepatide in significant weight loss is strong. The gap between what well-prescribed tirzepatide delivers and what the internet promises is still enormous. Here’s what to realistically expect.
What tirzepatide does well
- Produced meaningful average weight loss in clinical trials (mean ~15–22% over 72 weeks); individual results vary
- Improves A1c and fasting glucose in adults with type 2 diabetes (Mounjaro)
- Often lowers blood pressure and triglycerides alongside weight loss
- Reduces appetite for many patients
- Has cardiovascular safety data accumulating from SURPASS-CVOT and related trials
What it can’t do
- Replace strength training, sleep, protein, or stress management
- Be appropriate for patients with personal or family history of medullary thyroid carcinoma or MEN2
- Be a fit for patients with severe gastroparesis, active pancreatitis, or pregnancy
- Continue indefinitely without periodic reassessment of benefit, side effects, and goals
- Prevent regain if discontinued without a plan for ongoing metabolic care
- Be appropriately prescribed without baseline labs and a real clinical workup
Before you book.
How much does tirzepatide cost in Houston?
Consultations start at $49 (see pricing). Medication costs are separate and depend on what your provider prescribes and on your insurance coverage. Brand-name Mounjaro and Zepbound may be covered by some plans, and the manufacturer offers savings programs. Our ongoing program fees cover physician oversight, scheduled lab repeats, and dose adjustments — separate from medication costs. We discuss specifics during consultation, with no surprises.
How is FDA-approved Mounjaro or Zepbound different from compounded tirzepatide?
Mounjaro and Zepbound are FDA-approved drug products, manufactured under FDA oversight and supported by extensive clinical trial and post-market data. Compounded tirzepatide is not FDA-approved: it is prepared by licensed compounding pharmacies for individual patients, the FDA does not review it for safety, effectiveness, or quality, and it is not a generic version of, or interchangeable with, Mounjaro or Zepbound. The clinical trial results described on this page were obtained with the FDA-approved products. Compounding is permitted only in specific circumstances under current FDA rules, and quality varies significantly by pharmacy. We discuss the tradeoffs honestly during consultation. Read more about FDA-approved vs. compounded medications.
How is tirzepatide different from semaglutide?
Both medications activate GLP-1 receptors. Tirzepatide additionally activates GIP receptors, and in a head-to-head trial it produced greater average weight loss. SURMOUNT-1 (tirzepatide) showed mean reductions ~15–22% at varying doses over 72 weeks; STEP-1 (semaglutide) averaged ~14.9%. For some patients, semaglutide is the right starting point. For others, tirzepatide may be the better fit. We choose based on your history and goals, and help you decide which fits your specific picture.
What side effects should I expect?
The most common are GI: nausea, constipation, bloating, fullness, and occasional reflux. Most are mild to moderate and improve with slow dose titration. We start at the labeled starting dose (2.5mg weekly) and escalate only when tolerated. Less common but more serious effects include pancreatitis and gallbladder issues — which is why baseline labs and ongoing monitoring matter. We discuss all of this during consultation.
Will I gain the weight back when I stop?
Without a plan, yes — most patients regain a meaningful percentage of weight loss after discontinuing GLP-1 medications. This is the central question that determines whether tirzepatide is worth starting in the first place. Our approach: treat the medication as one phase of a longer metabolic conversation. We discuss what comes after — whether that’s a maintenance dose, transition to other medications, or our metabolic reset program — before you start, not after.
How long does it take to see results?
Many patients notice appetite changes early, and weight loss builds gradually as doses increase. In trials, average results of 15% or more took more than a year of consistent therapy. Individual results vary. We’re honest about timelines and willing to adjust if response isn’t materializing as expected.
Do you accept insurance?
Brand-name Mounjaro and Zepbound are sometimes covered for weight management or type 2 diabetes, depending on your specific plan. We provide documentation suitable for insurance submission but don’t bill insurers directly. Compounded tirzepatide is not covered by insurance. Some patients use HSA/FSA funds for consultations and ongoing program fees. Read about what to expect in your first 90 days on a GLP-1 for the broader expectations picture.
Start with a conversation, not a prescription.
A 45-minute consultation with one of our Houston providers. We’ll review your situation, decide together whether tirzepatide fits, and what comes next.